Compare

Bavarian Nordic A/S/€BAVA

1D1W1M3M6MYTD1Y5YMAX

About Bavarian Nordic A/S

Bavarian Nordic A/S is a biotechnology company based in Denmark, primarily focused on the development, manufacture, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company's product portfolio includes vaccines for smallpox, Ebola, and other infectious diseases, with its most notable products being the smallpox and monkeypox vaccine, Jynneos (also known as Imvanex or Imvamune). Founded in 1994, Bavarian Nordic has established partnerships with several government agencies, enhancing its strategic positioning in the vaccine development sector. The company operates globally, with its headquarters located in Kvistgaard, Denmark, and manufacturing facilities in various locations supporting its international distribution efforts. Bavarian Nordic leverages proprietary vaccine platform technologies such as MVA-BN, contributing to its competitive advantage in the biotechnology industry.
Ticker
€BAVA
Sector
Health
Primary listing
XGAT
Employees
1,906
Headquarters
Hellerup, Denmark
Website
www.bavarian-nordic.com

BAVA Metrics

BasicAdvanced
€2.4B
12.27
€2.60
0.94
-

What the Analysts think about BAVA

Analyst ratings (Buy, Hold, Sell) for Bavarian Nordic A/S stock.
Analyst projections of the future price of Bavarian Nordic A/S stock.

Bulls say / Bears say

Bavarian Nordic raised its 2026 revenue outlook to about DKK 6.1 billion and its EBITDA margin forecast to 32%, after stronger-than-expected Travel Health sales, particularly rabies vaccines in the US. That points to strong near-term trading and improved profitability. (Bavarian Nordic)
A new four-year UK government contract for scheduled supplies of its mpox and smallpox vaccine gives the Public Preparedness business longer-term order visibility. The contract value was not disclosed. (Bavarian Nordic)
The EU’s approval of MVA-BN for children aged two to under 12 broadens the vaccine’s approved reach. This could support future government and public-health procurement. (Bavarian Nordic)
US uptake of Vimkunya has been held back while distributors await a CDC recommendation, prompting Bavarian Nordic to cut its 2026 sales forecast for the chikungunya vaccine from DKK 250 million to DKK 200 million. This delays a potential source of growth. (Investing.com)
Public Preparedness revenue fell 53% year on year in Q1, which the company linked to a normalised year without a material mpox-outbreak contribution. This shows how government order timing and outbreak-related demand can make the segment’s revenue uneven. (Bavarian Nordic)
Management said some TBE vaccine products had been sold with relatively short shelf lives, which could lead to returns later in the year. Such returns would put pressure on sales and profitability. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.

BAVA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BAVA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.